Treatment of COVID-19 by CD24FC; a mini-review to the current knowledge
The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is already known for its respiratory infection, but it involved more organs such as the kidney, liver, and heart. Most of the patients with COVID-19 have mild symptoms, but 5% of cases are admitted to an intensive care unit (ICU) for s...
Main Authors: | Ghazal Ghasempour Dabaghi, Mehrdad Rabiee Rad, Lillian Saberian |
---|---|
Format: | Article |
Language: | English |
Published: |
Society of Diabetic Nephropathy Prevention
2021-01-01
|
Series: | Journal of Preventive Epidemiology |
Subjects: | |
Online Access: | https://jprevepi.com/PDF/jpe-6-e04.pdf |
Similar Items
-
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology
by: No-Joon Song, et al.
Published: (2022-01-01) -
CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma
by: Xiaofang Wu, et al.
Published: (2023-06-01) -
Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
by: Sophia Roßkopf, et al.
Published: (2020-11-01) -
Antigen-dependent modulation of immune responses to antigen-Fc fusion proteins by Fc-effector functions
by: Elie Richel, et al.
Published: (2023-10-01) -
Increased expressions of CD123, CD63, CD203c, and Fc epsilon receptor I on blood leukocytes of allergic asthma
by: Hua Xie, et al.
Published: (2022-08-01)